Axonics Intrinsic Stock Value – AXONICS Reports 34.7% Increase in Total Revenue for FY2023 Second Quarter
July 29, 2023
☀️Earnings Overview
On July 27 2023, AXONICS ($NASDAQ:AXNX) announced their fiscal year 2023 second quarter earnings results, showing total revenue had reached USD 92.9 million, a 34.7% increase from the same quarter in the previous year. Net income for the quarter was reported at USD -7.3 million, a great improvement on the -21.4 million from the prior year.
Analysis – Axonics Intrinsic Stock Value
GoodWhale conducted an analysis of AXONICS‘s wellbeing and determined that the fair value of AXONICS share was around $84.7. This value was calculated with GoodWhale’s proprietary Valuation Line, taking into account a number of factors, such as financial reports, market trends, and analyst ratings. At the time of this report, AXONICS stock was trading at $53.0, undervalued by 37.4%. This presents a great opportunity for investors to purchase AXONICS shares at a reduced cost. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Axonics. AXONICS_Reports_34.7_Increase_in_Total_Revenue_for_FY2023_Second_Quarter”>More…
| Total Revenues | Net Income | Net Margin |
| 319.85 | -32.18 | -1.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Axonics. AXONICS_Reports_34.7_Increase_in_Total_Revenue_for_FY2023_Second_Quarter”>More…
| Operations | Investing | Financing |
| 11.58 | -120.35 | 133.97 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Axonics. AXONICS_Reports_34.7_Increase_in_Total_Revenue_for_FY2023_Second_Quarter”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 648.99 | 48.46 | 11.9 |
Key Ratios Snapshot
Some of the financial key ratios for Axonics are shown below. AXONICS_Reports_34.7_Increase_in_Total_Revenue_for_FY2023_Second_Quarter”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 82.3% | – | -7.5% |
| FCF Margin | ROE | ROA |
| 2.8% | -2.5% | -2.3% |
Peers
The company’s products include the Axonics r-SNM System, a sacral neuromodulation system that is used to treat urinary incontinence and bowel dysfunction; and the Axonics Sacral Neuromodulation System, a rechargeable neuromodulation system that is used to treat urinary incontinence, bowel dysfunction, and sacral pain. Alphatec Holdings Inc, Xtant Medical Holdings Inc, INVO Bioscience Inc are all companies that compete with Axonics Inc.
– Alphatec Holdings Inc ($NASDAQ:ATEC)
Alphatec Holdings, Inc. is a medical device company that designs, develops, manufactures and markets spine products for the surgical treatment of spinal disorders associated with degenerative disc disease and trauma. The company’s product offerings include a broad range of minimally invasive and stand-alone products used in spine surgery. Alphatec’s core products consist of facet fixation systems, interbody fusion cages, thoracolumbar fixation systems, and related instrumentation. The company also offers a line of biologics products. Alphatec has a market cap of 1.07B as of 2022 and a return on equity of -374.34%.
– Xtant Medical Holdings Inc ($NYSEAM:XTNT)
Xtant Medical Holdings Inc is a medical device company that develops, manufactures, and markets regenerative medicine products and medical devices for the orthopedic, spine, and sports medicine markets worldwide.
The company has a market cap of $68.18 million and a return on equity of -14.12%. Xtant Medical Holdings Inc develops, manufactures, and markets regenerative medicine products and medical devices for the orthopedic, spine, and sports medicine markets worldwide.
– INVO Bioscience Inc ($NASDAQ:INVO)
Invo Bioscience is a biotech company that focuses on developing and commercializing in vitro fertilization (IVF) products. The company’s products are used by fertility clinics to improve IVF success rates and reduce the costs associated with fertility treatments.
Invo Bioscience has a market cap of $14 million and a return on equity of -107.22%. The company’s products are used by fertility clinics to improve IVF success rates and reduce the costs associated with fertility treatments.
Summary
AXONICS has reported a strong quarter for their fiscal year 2023, with total revenue increasing by 34.7% and net income improving significantly from the prior year. Investors may be encouraged by the growth seen in the quarter, which suggests that the company’s strategy of expanding its product portfolio and investing in its operations is paying off. The increased revenue and improved profitability indicates a positive outlook for the company and provides optimism for further growth over the rest of the year.
